In a first, FDA green-lights use of a Chi­nese built can­cer ther­a­py — and more are com­ing

Weeks af­ter Am­gen took a $2.7 bil­lion stake in BeiGene, the Bei­jing-based biotech has se­cured its first-ever FDA ap­proval for zanubru­ti­nib, a BTK in­hibitor, months ahead of sched­ule.

BeiGene’s drug, brand­ed as Brukin­sa, has se­cured ac­cel­er­at­ed ap­proval for adult pa­tients with man­tle cell lym­phoma (MCL) — a typ­i­cal­ly ag­gres­sive, rare, form of blood can­cer — who have re­ceived at least one pri­or ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER